09.01.08
Indication: Osteoarthritis (OA) of the knee
Source: Arthritis Res Ther, July 30, 2008;10(4):R85.
Research: Using a double-blind, placebo-controlled model, researchers assigned 75 patients to receive either 100 mg (n = 25) or 250 mg (n = 25) of 5-Loxin daily or a placebo (n = 25) for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools (visual analog scale, Lequesne’s Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index-WOMAC) at the baseline (day 0), and at days 7, 30, 60 and 90. Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid from OA patients.
Results: Seventy patients completed the study. In the end, both doses of 5-Loxin conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients. Interestingly, researchers said, significant improvements in pain score and functional ability were recorded in the treatment group supplemented with 250 mg 5-Loxin as early as 7 days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, they also noted significant reduction in synovial fluid matrix metalloproteinase-3. Researchers believe 5-Loxin may exert its beneficial effects by controlling inflammatory responses by reducing pro-inflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients.
Source: Arthritis Res Ther, July 30, 2008;10(4):R85.
Research: Using a double-blind, placebo-controlled model, researchers assigned 75 patients to receive either 100 mg (n = 25) or 250 mg (n = 25) of 5-Loxin daily or a placebo (n = 25) for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools (visual analog scale, Lequesne’s Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index-WOMAC) at the baseline (day 0), and at days 7, 30, 60 and 90. Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid from OA patients.
Results: Seventy patients completed the study. In the end, both doses of 5-Loxin conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients. Interestingly, researchers said, significant improvements in pain score and functional ability were recorded in the treatment group supplemented with 250 mg 5-Loxin as early as 7 days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, they also noted significant reduction in synovial fluid matrix metalloproteinase-3. Researchers believe 5-Loxin may exert its beneficial effects by controlling inflammatory responses by reducing pro-inflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients.